mRNA medicine with or without immunotherapy for advanced solid cancers
Treatments studied
Part of Cancer clinical trials.
This Phase 1/2 study tests an mRNA vaccine (mRNA-4359) either alone or combined with an immune checkpoint antibody (immunotherapy). It’s for people with advanced solid tumors to see if it can shrink tumors and how safe it is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18+ (or 12+ for one melanoma group) and can provide consent/assent before any study steps.
- You have advanced or metastatic cancer that matches one of the study types (such as melanoma, NSCLC, certain bladder/head and neck/colorectal/basal cell/triple-negative breast cancers).
- Your cancer must have measurable disease that can be tracked on scans, and you must have a tumor spot that can be biopsied plus another spot that can be followed for response.
- Your body must be able to tolerate treatment (ECOG status 0–1 and blood/organ tests adequate).
- For groups that involve PD-L1, your tumor must meet a required PD-L1 level (often confirmed with a central test on a biopsy).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two experimental mRNA vaccines (mRNA-4106 and mRNA-4200) given either alone or together with other cancer treatments. The goal is to see if they are safe and work against advanced or metastatic solid tumors like melanoma, lung, liver, and colon cancer. Participation requires that you have tried or refused all standard treatments.
This Phase 1/2 study tests a new cancer drug (S-531011) in people with advanced or metastatic solid tumors, either by itself or combined with an immunotherapy drug. It may help shrink tumors and learn how the treatment works, but it also requires extra procedures like repeat tumor biopsies and frequent monitoring.
This Phase 1/2 study tests a beta-only version of IL-2, an immune-stimulating treatment, to shrink or control advanced or metastatic solid tumors. It’s mainly designed to check safety and to see if it can help patients by improving tumor response.
This trial tests whether a personalized mRNA vaccine, given with pembrolizumab, can help people with advanced solid tumors by training the immune system to recognize cancer. It is mainly for patients whose tumor tissue matches specific genetic and immune patterns, and who meet key safety and infection requirements.
This early-stage trial tests a new mRNA-based drug designed to help your immune system fight advanced cancers that haven't responded to standard treatments. The study measures safety, tolerability, and whether it can slow or shrink your tumor.
This trial is testing an experimental mRNA vaccine (which targets a protein called circFAM53B-219aa found on tumor cells) combined with an immunotherapy drug (anti-PD-1) to treat advanced cancers that have stopped responding to standard treatments. The goal is to see if this combination is safe and effective for people with solid tumors like lung, breast, melanoma, pancreatic, and colon cancer.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.